A weekly shot tested for fast weight gain in teens after a brain tumor
Original title: SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a large, late stage trial in people.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests a weekly shot for teens who gained weight after a brain tumor.
Who this trial is for. This trial is for children ages 12 to 17 with craniopharyngioma, a rare brain tumor. They have gained a lot of weight because the tumor or its treatment harmed the hypothalamus. The trial tests a medicine called semaglutide against a placebo, which is a dummy shot.
Where it stands. This trial has not reported results. It is measuring whether semaglutide works for this kind of weight gain. Neither the patients nor the doctors know who gets the real shot. The answer is not in yet.
What this means, and what it doesn't
What it could mean: Weight gain after this tumor is common and hard to treat. The source says it is still a problem in 30 to 50% of cases. This trial asks if semaglutide can help these teens. A family whose child fits could ask their care team about it.
What it doesn't mean: This does not mean semaglutide is proven for this problem. A trial is a test, not a treatment you can count on. Joining one is not a promise that it will help. It is not a cure.
Source: ClinicalTrials.gov, September 29, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.